Results of 2025 Annual General Meeting MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 21 November 2025: In accordance with ASX Listing rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the attached informa

Results of 2025 Annual General Meeting

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA

- 21 November 2025: In accordance with ASX Listing rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the attached

information is provided in relation to the resolutions passed by the shareholders of Alterity Therapeutics Limited (ASX: ATH, NASDAQ:

ATHE) ("Alterity" or "the Company") at its Annual General Meeting held on 21 November 2025.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical

stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is

initially focused on developing disease modifying therapies in Parkinson's disease and related disorders. Alterity has demonstrated

clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double blind, placebo-controlled Phase 2 clinical trial in

participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive

data in its open label Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable

chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco,

California, USA. For further information please visit the Company's website at www.alteritytherapeutics.com.

Authorisation & Additional information

This announcement was authorised by David Stamler,

CEO of Alterity Therapeutics Limited.

Forward Looking Statements

This press release contains

"forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities

Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends,"

"hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates,"

and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that

could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections

titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form 20-F as

well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program,

including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including,

but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including,

but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory

approval, production and marketing of the Company's drug components, including, but not limited to, ATH434, the ability of the Company

to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's

drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining

patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company's

patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement

made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is

made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time

to time, whether as a result of new information, future developments or otherwise.